{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:06:41Z","timestamp":1788264401239,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.dmd.2026.100278","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:50:03Z","timestamp":1774425003000},"page":"100278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ketone reduction drives major circulating metabolites of GDC-8264 in humans"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3282-1343","authenticated-orcid":false,"given":"Shuai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9265-8381","authenticated-orcid":false,"given":"Antonio","family":"DiPasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4691-548X","authenticated-orcid":false,"given":"Allen Y.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3336-9994","authenticated-orcid":false,"given":"Teresa","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1078-3876","authenticated-orcid":false,"given":"Arturo L.","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuxi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Kshirsagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Cyrus","family":"Khojasteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8677-9737","authenticated-orcid":false,"given":"Donglu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.dmd.2026.100278_bib1","doi-asserted-by":"crossref","first-page":"23050","DOI":"10.1021\/acs.jmedchem.5c01891","article-title":"Discovery of clinical candidate GDC-8264, a novel, potent and selective RIP1 inhibitor for amelioration of tissue damage and the treatment of inflammatory diseases","volume":"68","author":"Patel","year":"2025","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.dmd.2026.100278_bib2","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1021\/acs.oprd.5c00125","article-title":"Stereocontrolled first generation synthesis of RIPK1 inhibitor GDC-8264","volume":"29","author":"Hong","year":"2025","journal-title":"Org Process Res Dev"},{"issue":"8","key":"10.1016\/j.dmd.2026.100278_bib3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41573-020-0071-y","article-title":"Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target","volume":"19","author":"Mifflin","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.dmd.2026.100278_bib4","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1111\/cts.13607","article-title":"A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteers","volume":"16","author":"Jones","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"4","key":"10.1016\/j.dmd.2026.100278_bib5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3109\/03602532.2015.1089885","article-title":"The modulation of carbonyl reductase 1 by polyphenols","volume":"47","author":"Bou\u0161ov\u00e1","year":"2015","journal-title":"Drug Metab Rev"},{"issue":"13","key":"10.1016\/j.dmd.2026.100278_bib6","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1016\/j.bmcl.2009.05.011","article-title":"N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11\u03b2-hydroxysteroid dehydrogenase type 1: discovery of PF-915275","volume":"19","author":"Siu","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"10.1016\/j.dmd.2026.100278_bib7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1021\/acsmedchemlett.8b00484","article-title":"Bioisosteres of indomethacin as inhibitors of aldo-keto reductase 1C3","volume":"10","author":"Lolli","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.dmd.2026.100278_bib8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0009-2797(02)00206-5","article-title":"Selective and potent inhibitors of human 20\u03b1-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone","volume":"143","author":"Higaki","year":"2003","journal-title":"Chem-Biol Interact"},{"issue":"23","key":"10.1016\/j.dmd.2026.100278_bib9","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/rcm.7055","article-title":"Unexpected peaks in tandem mass spectra due to reaction of product ions with residual water in mass spectrometer collision cells","volume":"28","author":"Neta","year":"2014","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"1","key":"10.1016\/j.dmd.2026.100278_bib10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/jasms.4c00336","article-title":"Molecular oxygen (O2) artifacts in tandem mass spectra","volume":"36","author":"Liang","year":"2025","journal-title":"J Am Soc Mass Spectrom"},{"issue":"1","key":"10.1016\/j.dmd.2026.100278_bib11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1107\/S0108767307043930","article-title":"A short history of SHELX","volume":"64","author":"Sheldrick","year":"2008","journal-title":"Acta Crystallogr Sect A"},{"issue":"1","key":"10.1016\/j.dmd.2026.100278_bib12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.taap.2015.07.023","article-title":"Vitamin K3 (menadione) redox cycling inhibits cytochrome P450-mediated metabolism and inhibits parathion intoxication","volume":"288","author":"Jan","year":"2015","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1\u20133","key":"10.1016\/j.dmd.2026.100278_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0009-2797(00)00304-5","article-title":"Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta","volume":"130","author":"Atalla","year":"2001","journal-title":"Chem-Biol Interact"},{"issue":"5","key":"10.1016\/j.dmd.2026.100278_bib14","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.xphs.2017.01.024","article-title":"Human tissue distribution of carbonyl reductase 1 using proteomic approach with liquid chromatography-tandem mass spectrometry","volume":"106","author":"Hua","year":"2017","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.dmd.2026.100278_bib15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0090-9556(25)07782-7","article-title":"Naltrexone disposition in man after subcutaneous administration","volume":"12","author":"Wall","year":"1984","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2026.100278_bib16","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3109\/00498258609043567","article-title":"The metabolism of 14C-oxcarbazepine in man","volume":"16","author":"Sch\u00fctz","year":"1986","journal-title":"Xenobiotica"},{"issue":"s3","key":"10.1016\/j.dmd.2026.100278_bib17","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/j.1528-1157.1994.tb05938.x","article-title":"Clinical pharmacology and pharmacokinetics of oxcarbazepine","volume":"35","author":"Lloyd","year":"1994","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.dmd.2026.100278_bib18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0378-4347(92)80459-4","article-title":"Determination of the R-(\u2212) and S-(+) enantiomers of the monohydroxylated metabolite of oxcarbazepine in human plasma by enantioselective high-performance liquid chromatography","volume":"581","author":"Flesch","year":"1992","journal-title":"J Chromatogr"},{"issue":"6","key":"10.1016\/j.dmd.2026.100278_bib19","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/dta.1541","article-title":"Characterizing metabolites and potential metabolic pathways for the novel psychoactive substance methoxetamine","volume":"6","author":"Menzies","year":"2014","journal-title":"Drug Test Anal"},{"issue":"3","key":"10.1016\/j.dmd.2026.100278_bib20","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00216-010-3636-5","article-title":"Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography\u2013mass spectrometry","volume":"397","author":"Meyer","year":"2010","journal-title":"Anal Bioanal Chem"},{"issue":"10","key":"10.1016\/j.dmd.2026.100278_bib21","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1124\/dmd.108.022251","article-title":"Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver","volume":"36","author":"Kassner","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100278_bib22","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1124\/dmd.118.081083","article-title":"11\u03b2-hydroxysteroid dehydrogenase 1 human tissue distribution, selective inhibitor, and role in doxorubicin metabolism","volume":"46","author":"Yang","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100278_bib23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bcp.2016.03.025","article-title":"Carbonyl reduction of warfarin: identification and characterization of human warfarin reductases","volume":"109","author":"Mal\u00e1tkov\u00e1","year":"2016","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"10.1016\/j.dmd.2026.100278_bib24","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1124\/dmd.117.075929","article-title":"Stereospecific metabolism of R- and S-warfarin by human hepatic cytosolic reductases","volume":"45","author":"Barnette","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100278_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/dmd.120.000220","article-title":"Absorption, metabolism, and excretion, in vitro pharmacology, and clinical pharmacokinetics of ozanimod, a novel sphingosine 1-phosphate receptor modulator","volume":"49","author":"Surapaneni","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100278_bib26","first-page":"543","article-title":"Microsomal carbonyl reductase responsible for reduction of 4-phenyl-3-buten-2-one in rats","volume":"48","author":"Okamoto","year":"1999","journal-title":"IUBMB Life"},{"issue":"4","key":"10.1016\/j.dmd.2026.100278_bib27","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/dmd.30.4.414","article-title":"Reductive metabolism of an \u03b1,\u03b2-ketoalkyne, 4-phenyl-3-butyn-2-one, by rat liver preparations","volume":"30","author":"Kitamura","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100278_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2024.100027","article-title":"In vitro metabolism of targeted covalent inhibitors and their thiol conjugates by gut microbiome from rats, mice, and humans","volume":"53","author":"Gu","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100278_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1128\/AAC.03861-14","article-title":"Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor","volume":"59","author":"Chen","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.dmd.2026.100278_bib30","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1124\/dmd.118.082487","article-title":"Identification and characterization of a selective human carbonyl reductase 1 substrate","volume":"46","author":"Ramsden","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"28","key":"10.1016\/j.dmd.2026.100278_bib31","doi-asserted-by":"crossref","first-page":"25677","DOI":"10.1074\/jbc.M202160200","article-title":"Critical residues for structure and catalysis in short-chain dehydrogenases\/reductases","volume":"277","author":"Filling","year":"2002","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.dmd.2026.100278_bib32","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/dmd.109.031179","article-title":"Metabolism of intravenous methylnaltrexone in mice, rats, dogs, and humans","volume":"38","author":"Chandrasekaran","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100278_bib33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/00498254.2022.2062487","article-title":"Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans","volume":"52","author":"Ryder","year":"2022","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.dmd.2026.100278_bib34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1124\/dmd.109.031476","article-title":"The Metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans","volume":"38","author":"Blech","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2026.100278_bib35","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1124\/dmd.120.000309","article-title":"Metabolism and mass balance of the novel nonsteroidal androgen receptor inhibitor darolutamide in humans","volume":"49","author":"Taavitsainen","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100278_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/00498254.2014.945988","article-title":"Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite","volume":"45","author":"Krauser","year":"2015","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmd.2026.100278_bib37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/dmd.122.000867","article-title":"Stereoselective metabolism of bupropion to active metabolites in cellular fractions of human liver and intestine","volume":"51","author":"Bamfo","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2026.100278_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007113","article-title":"Structural basis for substrate specificity in human monomeric carbonyl reductases","volume":"4","author":"Pilka","year":"2009","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.dmd.2026.100278_bib39","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1124\/dmd.113.051177","article-title":"Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes","volume":"41","author":"Nishimuta","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100278_bib40","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1124\/mol.107.035550","article-title":"Functional characterization of the promoter of human carbonyl reductase 1 (CBR1). Role of XRE elements in mediating the induction of CBR1 by ligands of the aryl hydrocarbon receptor","volume":"72","author":"Lakhman","year":"2007","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100278_bib41","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0090-9556(25)08629-5","article-title":"Carbonyl (phenone) reductase in human liver: structure-activity relationship among substrates","volume":"20","author":"Wong","year":"1992","journal-title":"Drug Metab Dispos"},{"issue":"24","key":"10.1016\/j.dmd.2026.100278_bib42","doi-asserted-by":"crossref","first-page":"10512","DOI":"10.1021\/jm5016022","article-title":"Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes","volume":"57","author":"Griffith","year":"2014","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.dmd.2026.100278_bib43","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1021\/acs.jmedchem.0c01720","article-title":"Intestinal excretion, intestinal recirculation, and renal tubule reabsorption are underappreciated mechanisms that drive the distribution and pharmacokinetic behavior of small molecule drugs","volume":"64","author":"Zhang","year":"2021","journal-title":"J Med Chem"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:13:42Z","timestamp":1779790422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0090955626000474"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100278","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketone reduction drives major circulating metabolites of GDC-8264 in humans","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100278"}}